Vesicor Therapeutics and Black Hawk Acquisition Corporation Announce Closing of Business Combination

On November 20, 2026 Vesicor Therapeutics Holdings, Inc. ("Vesicor" or the "Company"), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, reported the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) ("Black Hawk"). The transaction was approved by Black Hawk’s shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol "VESI" on November 23, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vesicor will be led by Michael Tolentino, MD, Chief Executive Officer; Luo Feng, PhD, Founder, Director and Chief Scientific Officer; Mitch Creem, MHA, Chief Financial Officer; and Warren Hosseinion, Jr., Chief Operating Officer. The Company’s Board of Directors consists of Warren Hosseinion, Sr., MD (Chairman), Luo Feng, PhD, Oded Levy, Frederick Woodruff Field and Qi Ouyang.

"Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most, as we prepare to begin IND-enabling studies for ecm-RV/p53," said Warren Hosseinion, Sr., MD, Chairman of the Board. "I want to thank our shareholders and the Vesicor team for the work that brought us here. Our focus now is execution."

"I founded Vesicor in 2008 with the goal of developing p53-based cancer therapeutics using precision-engineered microvesicles," said Luo Feng, PhD, Founder, Director and Chief Scientific Officer. "ecm-RV/p53 reflects many years of research, and we are focused on building on that foundation as we seek to advance the program toward clinical evaluation."

"Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA," said Michael Tolentino, MD, Chief Executive Officer. "We have a defined goal, an experienced team and a board that has the skills to advance the priorities of the Company. We look forward to reporting our progress to shareholders."

Advisors

Celine & Partners, P.L.L.C. and Ogier Global (Cayman) Limited served as legal counsel to Black Hawk. D. Boral Capital LLC served as the capital markets advisor to Black Hawk. PW Richter PLC, Winston Taylor LLP, and Shartsis Friese LLP served as legal counsel to Vesicor.

(Press release, Vesicor Therapeutics, NOV 20, 2026, View Source [SID1234675051])